Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered blood test aims to spot colorectal cancer

NCT ID NCT06889844

Diagnosis Sponsor: ADVANCED MARKER DISCOVERY S.L. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new blood test that uses artificial intelligence to find markers for colorectal cancer. Researchers want to see how often the test gives a false positive result in 250 people who have other cancers or gut diseases. Participants give one blood sample, and their medical records are checked for risk factors. The goal is to make colorectal cancer diagnosis easier and more accurate.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
blood test
What this could lead to
If successful, this could lead to a simple, accurate blood test to help diagnose colorectal cancer earlier.
What could go wrong
This is an early observational study, not a treatment trial. The test may still have false positives or not work as well in larger, more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients will be enrolled with a only one diagnosis of cancer (no colorectal cancer) or gastrointestinal disease at the time of a consultation within the Oncology, Digestive System, Gastroenterology, Endoscopy or Surgery Service. Patients will be included in a competitive, consecutive and progressive manner by the Centers.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients older than 18 years of age at the time of blood sample collection. * Subjects must be able to understand the information provided on the participant information sheet, must consent to participate in the study, and must sign the informed consent form. * Patients diagnosed with only one type of cancer (no colorectal cacner) or gastrointestinal disease. Exclusion Criteria: * Patients who have received previous chemotherapy or radiotherapy. * In case of diagnosis of a tumor: patients who have undergone total or partial surgical resection of the tumor. * Patients with a personal history of advanced or non-advanced colorectal adenoma, serrated lesions, colorectal cancer, familial adenomatous polyposis or Lynch syndrome. * Patients without appropriate staging or diagnosis. * Patients with hemolyzed plasma.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Centro Médico Asturias

    RECRUITING

    Oviedo, Cantabria, Spain

  • Hospital Universitario HM Sanchinarro

    RECRUITING

    Madrid, Madrid, Spain

  • Hospital Universitario de Ourense

    RECRUITING

    Ourense, Galicia, Spain

  • Hospitales HM de Malaga

    RECRUITING

    Málaga, Andalusia, Spain

  • MD Anderson Cancer Centre

    ACTIVE_NOT_RECRUITING

    Madrid, Madrid, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.